Patients
Reveal Expanded Access Policy
Expanded access, sometimes called compassionate use, refers to the use of an investigational new drug outside of a clinical trial for patients with serious or life-threatening conditions who have exhausted their treatment options and are not eligible for, or able to participate in, a clinical trial. Reveal Pharmaceuticals is committed to advancing new contrast agents for patients requiring medical imaging (e.g., MRI) to detect and visualize lesions in the central nervous system (CNS) and body. We are working to bring our new manganese-based MRI contrast agent to patients as quickly and safely as possible through our clinical development program.
Because we are actively in clinical studies of our lead candidate, RVP-001, we are not currently providing access outside of clinical trials. At this time, we believe participation in a clinical trial is the optimal way to access these investigational agents to enable thorough evaluation and support regulatory approvals.
This policy is subject to change and may be revised by Reveal at any time.
About Reveal Pharmaceuticals
Reveal is working to transform medical imaging, improve human health, and positively impact the environment. More than 40 million contrast-enhanced magnetic resonance imaging (MRI) scans are performed each year.
Current MRI contrast agents depend on gadolinium, a rare earth element with patient, environmental, and supply chain concerns. Reveal's patented contrast agents use manganese, a globally abundant element. Reveal's clinical-stage product RVP-001 aims to directly replace current MRI contrast agents, with potential impact for patients, the environment, and supply chain security.
For more information, contact info@revealpharma.com.